



## ORIGINAL ARTICLE

# Prognostic significance of a combined and controlled nutritional status score and EBV-DNA in patients with advanced nasopharyngeal carcinoma: a long-term follow-up study

Hui Lu<sup>1,2\*</sup>, Shanshan Guo<sup>1,3\*</sup>, Liting Liu<sup>1,3\*</sup>, Qiuyan Chen<sup>1,3</sup>, Yujing Liang<sup>1,3</sup>, Sailan Liu<sup>1,3</sup>, Xuesong Sun<sup>1,3</sup>, Qingnan Tang<sup>1,3</sup>, Xiaoyun Li<sup>1,3</sup>, Ling Guo<sup>1,3</sup>, Haoyuan Mo<sup>1,3</sup>, Linquan Tang<sup>1,3</sup>, Haiqiang Mai<sup>1,3</sup>

<sup>1</sup>State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, China; <sup>2</sup>Department of Radiation Oncology, Guangzhou Concord Cancer Center, Guangzhou 510045, China; <sup>3</sup>Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou 510060, China

### ABSTRACT

**Objective:** Several studies have reported that the controlling nutritional status (CONUT) score is a prognostic predictor for survival among patients with different types of cancer. We assessed the prognostic value of changes in the CONUT score during treatment and the  $\Delta$ CONUT-EBV DNA score in patients with advanced nasopharyngeal carcinoma (NPC).

**Methods:** We retrospectively analyzed 433 patients with advanced NPC having no evidence of metastasis from January 2007 to June 2011; the patients underwent radical concurrent chemoradiotherapy (CCRT) at Sun Yat-sen University Cancer Center and were grouped based on their  $\Delta$ CONUT and  $\Delta$ CONUT-EBV DNA scores. Kaplan-Meier curves were used to compare the patient outcomes according to the cut-off  $\Delta$ CONUT score and the  $\Delta$ CONUT-EBV DNA scoring system.

**Results:** Among all patients, overall survival (OS) was independently predicted by a high  $\Delta$ CONUT score ( $P = 0.031$ ) and high EBV DNA ( $P < 0.001$ ). The  $\Delta$ CONUT-EBV DNA score [OS area under the curve (AUC) = 0.621; progression free survival (PFS)-AUC = 0.612; distant metastasis-free survival (DMFS)-AUC = 0.622] was more predictive of OS, PFS, and DMFS in patients with advanced NPC than the  $\Delta$ CONUT score (OS-AUC = 0.547; PFS-AUC = 0.533; DMFS-AUC = 0.522) and pretreatment plasma EBV DNA levels alone (OS-AUC = 0.600; PFS-AUC = 0.591, DMFS-AUC = 0.610). The  $\Delta$ CONUT-EBV DNA score was significantly correlated with OS, PFS, and DMFS in patients with advanced NPC treated with CCRT.

**Conclusions:** The  $\Delta$ CONUT-EBV DNA score may be useful in clinical practice as a convenient biomarker for predicting the outcomes in patients with advanced NPC treated with CCRT.

### KEYWORDS

Controlling nutritional status score; Epstein-Barr virus deoxyribonucleic acid; nasopharyngeal carcinoma; prognosis; predictive factor

## Introduction

Nasopharyngeal carcinoma (NPC) is one of the most prevalent malignancies in Southeast Asia, including southern China<sup>1</sup>.

Epstein-Barr virus deoxyribonucleic acid (EBV DNA) has been used as a plasma marker for population screening<sup>2</sup>, prognoses<sup>3</sup>, and disease recurrence surveillance<sup>4,5</sup>. Owing to the high sensitivity of irradiation, radiotherapy alone and concurrent chemoradiotherapy (CCRT) are the primary treatments for nonmetastatic NPC. Moreover, intensity-modulated radiotherapy (IMRT) is the currently preferred method, because it reduces the risk of short-term side effects and long-term sequelae<sup>6</sup>. Over the years, immune-nutritional scores, such as the body mass index (BMI)<sup>7</sup>, albumin-globulin ratio<sup>8</sup>, and prognostic nutritional index (PNI)<sup>9,10</sup>, have been reported to be prognostic markers that influence NPC treatment outcomes.

Recently, studies have shown that the controlling nutritional status (CONUT) score, a novel immunological and

\*These authors contributed equally to this work.

Correspondence to: Linquan Tang and Haiqiang Mai  
E-mail: tanglq@sysucc.org.cn and maihq@sysucc.org.cn  
ORCID ID: <https://orcid.org/0000-0003-0214-203X>  
and <https://orcid.org/0000-0002-9613-7305>

Received October 08, 2020; accepted December 25, 2020; published online June 16, 2021.

Available at [www.cancerbiomed.org](http://www.cancerbiomed.org)

©2022 Cancer Biology & Medicine. Creative Commons Attribution-NonCommercial 4.0 International License

nutritional score, is a prognostic predictor for survival prognosis in many cancer types<sup>11-16</sup>. This score is calculated from the total lymphocyte count, total cholesterol, and serum albumin levels<sup>17</sup>. However, data on the prognostic value of the CONUT score for patients with advanced NPC are still unavailable. Moreover, the point at which the nutritional score should be measured during anti-cancer treatment remains unclear. Thus, this study aimed to clarify the prognostic and predictive values of the CONUT score at different time points to predict survival among patients with advanced NPC.

However, nutritional scores, such as the CONUT score, PNI, and BMI, are not always reliable in predicting the outcomes of cancers, because they lack tumor-related factors. Previous reports have suggested that tumor-related factors, such as the EBV DNA level<sup>3</sup> and tumor node metastasis (TNM) stage<sup>18,19</sup>, are likely the most reliable prognostic predictors for NPC. Plasma marker EBV DNA has been used for screening<sup>2</sup>, prognoses<sup>3</sup>, and disease recurrence surveillance<sup>4,5</sup>. Lin et al.<sup>20</sup> reported an inferior overall survival (OS) in patients with higher baseline plasma EBV DNA levels. The addition of pretreatment plasma EBV DNA to the 8<sup>th</sup> edition of the AJCC/UICC TNM stage classification greatly improved its prognostic performance<sup>21-23</sup>. Many studies support a positive relationship between the plasma EBV DNA level and tumor burden<sup>24,25</sup>. Unfortunately, cut-off values of plasma EBV DNA levels varied across these studies, and an optimal cut-off value of this liquid biopsy marker is still being determined<sup>26,27</sup>. Here, we characterized the complementary role of the  $\Delta$ CONUT score in combination with pretreatment plasma EBV DNA. The  $\Delta$ CONUT-EBV DNA score, which is based on the  $\Delta$ CONUT score and pretreatment plasma EBV DNA, was integrated with nutritional score and tumor-related factors, so it may have more prognostic information compared to only 1 parameter.

## Materials and methods

### Patients and study design

We retrospectively included and analyzed 433 patients with advanced NPC, but with no evidence of metastasis (M0) from January 2007 to June 2011, who underwent radical CCRT at Sun Yat-sen University Cancer Center. The exclusion and inclusion criteria were as follows: (I) patients with newly-diagnosed and pathologically proven NPC; (II) patients with complete clinical information and follow-up data; (III)

patients with complete laboratory data; (IV) patients who underwent radical CCRT during the course of anti-cancer treatment; (V) patients without other malignant cancers, serious illnesses (severe acute or chronic diseases); (VI) patients without distant metastasis; and (VII) patients with confirmed locoregionally advanced (stages II–IVA) NPC, as defined by the 2010 Union for International Cancer Control (UICC) system (**Supplementary Figure S1**). Laboratory data and clinical and epidemiological characteristics of the patients, such as age, gender, date of diagnosis, UICC T stage, UICC N stage, clinical stage, total lymphocyte count (/mm<sup>3</sup>), total cholesterol (mg/dL) and serum albumin (g/dL) levels, were assessed from their medical records. All patients were followed-up until April 2020 or until death. Our study protocol was approved by the ethics committee of Sun Yat-sen University Cancer Center (Approval No. GZR2014-069).

### Treatment strategies

Institutional guidelines recommend CCRT  $\pm$  neoadjuvant/adjuvant chemotherapy (CCRT  $\pm$  NC/AC) for patients with stage II–IVA NPC. In the present study, 397 (91.7%) of the patients received CCRT only, 24 (5.5%) received CCRT + AC, and 12 (2.8%) received CCRT + NC. All patients received IMRT. The prescribed doses were 66–70 Gy to the primary tumor and 54–64 Gy to the involved cervical lymph nodes and low risk clinical target volume.

### The CONUT score and cut-off value

The CONUT score was calculated based on the total cholesterol level, total lymphocyte counts, and serum albumin level (**Supplementary Table S1**)<sup>17</sup>. Pretreatment laboratory data (pre-CONUT score) were obtained within 14 days before anti-cancer treatment. Post-CONUT scores were calculated based on the results of blood tests within 5 days before the completion of CCRT. Individual difference value ( $\Delta$ CONUT score) of the post-treatment to pretreatment CONUT score was calculated as follows: (post - CONUT score) - (pre-CONUT score). The area under the curve (AUC) estimation method was used to determine the predictive value of the pretreatment CONUT score, the post-treatment CONUT score, and the  $\Delta$ CONUT score for OS. The receiver operating characteristic (ROC) curve analysis method was used to determine the optimal  $\Delta$ CONUT score cut-off value that was significantly correlated with OS.

## Definition of the $\Delta$ CONUT-EBV DNA score

The cut-off value of the  $\Delta$ CONUT score was 3, which was used as the criterion to divide the included 433 patients into  $\Delta$ CONUT-low (score  $\leq 3$ ) and  $\Delta$ CONUT-high (score  $> 3$ ) groups. The median cut-off value of EBV DNA was considered in all patients. The patients were divided into the following 2 groups according to the cut-off value of pretreatment plasma EBV DNA level (2,110 copies/mL): EBV DNA-low (score  $\leq 2,110$  copies/mL) and EBV DNA-high (score  $> 2,110$  copies/mL) groups. Based on the cut-off values of the  $\Delta$ CONUT score and pretreatment plasma EBV DNA, the  $\Delta$ CONUT-EBV DNA score was defined. Patients with an EBV DNA score of  $\leq 2,110$  copies/mL [ $N = 217$ ; low-risk group (LRG)] were assigned a score of 1; those with both a  $\Delta$ CONUT score of  $\leq 3$  and an EBV DNA score of  $> 2,110$  copies/mL [ $N = 170$ ; middle-risk group (MRG)] were assigned a score of 2; and those with both a  $\Delta$ CONUT score of  $> 3$  and an EBV DNA score of  $> 2,110$  copies/mL [ $N = 46$ ; high risk group (HRG)] were assigned a score of 3 (Table 3).

## Follow-up

All the patients were routinely followed up every 3–4 months throughout the first 2 years, every 6 months for the next 2 years, and annually thereafter, and were monitored either until April 2020 or until death. OS was defined as the period from the initial diagnosis to the patient's death or last follow-up, regardless of whether it was or was not related to NPC. The median follow-up period was 9.52 (range, 8.88–10.74) years. The following end points (time to the first defining event) were assessed: OS, progression-free survival (PFS), and DMFS.

## Statistical analysis

Pathological and clinical characteristics, and laboratory data were compared between the 2 groups using Fisher's exact test. Survival curves were estimated using the Kaplan-Meier method with the log-rank test. Univariate and multivariate analyses were performed using the Cox proportional hazards model. In all patients, the median cut-off values were considered for age and EBV DNA. Age (cut-off: 46 years), gender (female/male), UICC T stage (T1–2, T3–4), UICC N stage (N0–1, N2–3), clinical stage (stage II, stage III–IVA), EBV DNA score (cut-off: 2,110 copies/mL), and  $\Delta$ CONUT score (cut-off, 3) were the parameters considered in the Cox proportional hazards

model. To further investigate the characteristics of patients between the different  $\Delta$ CONUT-EBV DNA score groups, we performed further experiments. Fisher's exact test with a two-sided significance level was used to compare the pathological and clinical characteristics, and laboratory data between the different  $\Delta$ CONUT-EBV DNA score groups; all characteristics are shown in Table 1 before the Bonferroni-Holm correction was included. These analyses were also corrected for testing using the Bonferroni-Holm method. All data were analyzed using SPSS statistical software for Windows, version 22.0 (SPSS, Chicago, IL, USA). All  $P$  values were two-sided.  $P < 0.05$  and Bonferroni-corrected  $P < 0.05$  were considered statistically significant.


## Results

### Clinical and pathological characteristics, and treatment outcomes

A total of 397 (91.7%) patients received CCRT only, 24 (5.5%) received CCRT + AC, and 12 (2.8%) received CCRT + NC. All patients in this cohort received IMRT. Of the 433 patients, 39 (9.0%) developed locoregional recurrence, 75 (17.3%) developed distant metastases, and 98 (22.6%) died. The 5-year OS, PFS, and DMFS were 86.4%, 77.8%, and 84.2%, respectively.

We used the continuous variable pre-CONUT, post-CONUT, and  $\Delta$ CONUT scores as the test variables, and OS as the state variable. The  $\Delta$ CONUT score AUC was 0.547 [95% confidence interval (CI): 0.479–0.615], which was higher than the AUC of the other CONUT scores [pre-CONUT score (AUC = 0.453; 95% CI: 0.387–0.520) and post-CONUT score (AUC = 0.526; 95% CI: 0.458–0.594)] (Figure 1A). According to the ROC curve analysis results, the optimal  $\Delta$ CONUT score cut-off value that significantly correlated with OS was 3 (AUC = 0.547; Figure 1A).

Based on the  $\Delta$ CONUT score cut-off determined using the ROC curve analysis, the 433 patients were subdivided into the  $\Delta$ CONUT-low (score  $\leq 3$ ;  $N = 345$ ) and  $\Delta$ CONUT-high (score  $> 3$ ;  $N = 88$ ) groups. The clinical and demographic characteristics of the patients in the 2 groups are shown in Table 1. Age, gender, cancer stage, histology, smoking status, EBV DNA levels, viral capsid antigen (VCA)/immunoglobulin a (IgA) titers, and early antigen (EA)/IgA titer distributions did not significantly differ between the 2 groups (Table 1).



**Figure 1** (A) Receiver operating characteristic (ROC) curve analysis of the pretreatment controlling nutritional status (CONUT), post-treatment CONUT, and  $\Delta$ CONUT scores of interest for predicting overall survival (OS). (B) OS based on the  $\Delta$ CONUT score.

**Figure 1B** shows the Kaplan-Meier curves for OS according to the  $\Delta$ CONUT score-based groups. The patients in the  $\Delta$ CONUT-high group were more likely to experience a shorter OS than those in the  $\Delta$ CONUT-low group (**Figure 1B**;  $P = 0.030$ ). The 5-year OS rates for patients with low and high  $\Delta$ CONUT scores were 88.7% and 77.3%, respectively.

### Prognostic value of the $\Delta$ CONUT score

Univariate analyses identified an age  $> 46$  years ( $P = 0.011$ ), male ( $P = 0.008$ ), advanced N stage ( $P = 0.003$ ), high  $\Delta$ CONUT score ( $P = 0.031$ ), and high EBV DNA level ( $P < 0.001$ ) as factors significantly associated with a worse OS (**Table 2**). Multivariable analyses showed that age [hazard ratio (HR): 1.580; 95.0% CI: 1.054–2.369;  $P = 0.027$ ], gender (HR: 1.937; 95.0% CI: 1.115–3.367;  $P = 0.019$ ), N stage (HR: 1.597; 95.0% CI: 1.060–2.406;  $P = 0.025$ ), EBV DNA level (HR: 1.753; 95.0% CI: 1.142–2.693;  $P = 0.010$ ), and  $\Delta$ CONUT score (HR: 1.574; 95.0% CI: 1.009–2.454;  $P = 0.045$ ) were independent prognostic factors for OS (**Table 2**).

### Prognostic values of the $\Delta$ CONUT-EBV DNA score

In addition, patients were stratified according to their pretreatment plasma EBV DNA levels. The results showed that the  $\Delta$ CONUT score was not associated with OS in patients with low EBV DNA levels ( $\leq 2,110$  copies/mL; **Figure 2A**). Notably, the high  $\Delta$ CONUT score group had a significantly worse OS than the low  $\Delta$ CONUT score group, but only for patients with high pretreatment plasma EBV DNA levels ( $> 2,110$  copies/mL;  $P = 0.014$ ; **Figure 2B**).

We then suspected that the pretreatment plasma EBV DNA level could help improve the prognostic value of  $\Delta$ CONUT in patients with advanced NPC. The  $\Delta$ CONUT-EBV DNA score, a novel prognostic marker, was calculated based on the  $\Delta$ CONUT score and the pretreatment plasma EBV DNA level (**Table 3**). Using this  $\Delta$ CONUT-EBV DNA scoring system, we divided patients into low-risk (LRG;  $N = 217$ ), middle-risk (MGR;  $N = 170$ ), and high-risk (HRG;  $N = 46$ ) groups (**Table 3**). The baseline characteristics of the different groups are shown in **Table 4**. Patients with a low  $\Delta$ CONUT-EBV DNA score had earlier UICC N stages (Bonferroni-Holm corrected  $P = 0.003$ ), earlier clinical stages (Bonferroni-Holm corrected  $P = 0.006$ ), and lower EA/IgA values (Bonferroni-Holm corrected;  $P = 0.036$ ) than patients with a medium  $\Delta$ CONUT-EBV DNA score (MRG). Significant differences were present between LRG and HRG in the UICC N stage (Bonferroni-Holm corrected;  $P < 0.001$ ), but other variables were not significantly different. There was no significant difference in the age, gender, stage, histology, smoking status, VCA/IgA titers, and EA/IgA titers between the HRG and MRG (**Table 4**).

ROC analysis was used to evaluate the effect of the  $\Delta$ CONUT score, pretreatment plasma EBV DNA level, and  $\Delta$ CONUT-EBV DNA score on the prognosis. The results showed that the  $\Delta$ CONUT-EBV DNA scores (OS: AUC = 0.621, 95% CI: 0.556–0.685; PFS: AUC = 0.612, 95% CI: 0.552–0.672; DMFS: AUC = 0.622, 95% CI: 0.552–0.672; **Figure 3A–3C**) were more predictive of OS, PFS, and DMFS in patients with advanced NPC than the  $\Delta$ CONUT scores (OS: AUC = 0.547, 95% CI: 0.480–0.613; PFS: AUC = 0.533, 95% CI: 0.472–0.594; DMFS: AUC = 0.522, 95% CI: 0.449–0.595; **Figure 3A–3C**) or pretreatment plasma EBV DNA levels alone (OS: AUC = 0.600, 95% CI: 0.537–0.663; PFS:

**Table 1** Baseline characteristics of 433 patients with locoregionally advanced nasopharyngeal carcinoma


Characteristics	$\Delta$ CONUT > 3 N = 88 (%)	$\Delta$ CONUT $\leq$ 3 N = 345 (%)	P
Age (years)			1
$\leq$ 46	47 (53.4)	183 (53.0)	
>46	41 (46.6)	162 (47.0)	
Gender			0.177
Female	18 (20.5)	96 (27.8)	
Male	70 (79.5)	249 (72.2)	
UICC T stage			0.886
1	6 (6.8)	17 (4.1)	
2	17 (19.3)	63 (18.3)	
3	49 (55.7)	202 (58.6)	
4	16 (18.2)	66 (19.1)	
UICC N stage			0.603
0	13 (14.8)	39 (11.3)	
1	32 (36.4)	151 (43.8)	
2	35 (39.8)	127 (36.8)	
3	8 (9.1)	28 (8.1)	
Clinical stage			0.957
II	8 (9.1)	28 (8.1)	
III	57 (64.8)	226 (65.5)	
IV	23 (26.1)	91 (26.4)	
WHO histology			0.518
II	4 (4.5)	11 (3.2)	
III	84 (95.5)	334 (96.8)	
Smoking status			0.928
Non-smoker	53 (60.2)	215 (62.3)	
Ex-smoker	6 (6.8)	21 (6.1)	
Current smoker	29 (33.0)	109 (31.6)	
EBV DNA (copies/mL)			0.635
$\leq$ 2,110	42 (47.7)	175 (50.7)	
>2,110	46 (52.3)	170 (49.3)	
VCA/IgA titers			0.349
$\leq$ 80	28 (31.8)	91 (26.4)	
>80	60 (68.2)	254 (73.6)	
EA/IgA titers			0.066
$\leq$ 20	62 (70.5)	206 (59.7)	
>20	26 (29.5)	139 (40.3)	

CONUT, controlling nutritional status score; N stage, node stage; T stage, tumor stage; UICC, Union for International Cancer Control; WHO, World Health Organization; EBV DNA, Epstein-Barr virus deoxyribonucleic acid; VCA, viral capsid antigen; EA, early antigen; IgA, immunoglobulin a.

**Table 2** Univariate and multivariate analysis for OS

Variable	Univariate analysis		Multivariate analysis	
	HR (95% CI)	<i>P</i>	HR (95% CI)	<i>P</i>
Age	1.681 (1.125–2.512)	0.011	1.580 (1.054–2.369)	0.027
Gender	2.105 (1.214–3.648)	0.008	1.937 (1.115–3.367)	0.019
UICC T stage	0.922 (0.578–1.471)	0.734	0.796 (0.464–1.365)	0.955
UICC N stage	1.821 (1.219–2.720)	0.003	1.597 (1.060–2.406)	0.025
Clinical stage	3.077 (0.975–9.712)	0.055	2.591 (0.713–9.413)	0.214
$\Delta$ CONUT score	1.627 (1.045–2.535)	0.031	1.574 (1.009–2.454)	0.045
EBV DNA	2.116 (1.396–3.207)	<0.001	1.753 (1.142–2.693)	0.010

OS, overall survival; HR, hazard ratio; CI, confidence interval; N stage, node stage; T stage, tumor stage; UICC, Union for International Cancer Control; CONUT score, controlling nutritional status score; EBV DNA, Epstein-Barr virus deoxyribonucleic acid.



**Figure 2** Survival curves of patients in different Epstein-Barr virus deoxyribonucleic acid (EBV DNA) groups. (A) Overall survival (OS) based on the  $\Delta$ CONUT score in 217 patients with advanced nasopharyngeal carcinoma (NPC) with EBV DNA  $\leq$  2,110 copies/mL. (B) OS based on the  $\Delta$ CONUT score in 216 patients with advanced NPC with EBV DNA  $>$  2,110 copies/mL.

**Table 3**  $\Delta$ CONUT-EBV DNA score based on risk stratification with CONUT scores and EBV DNA for advanced nasopharyngeal carcinoma patients

$\Delta$ CONUT-EBV group	$\Delta$ CONUT-EBV score	$\Delta$ CONUT score	EBV DNA
Low-risk group	1	–	$\leq$ 2,110
Middle-risk group	2	$\leq$ 3	$>$ 2,110
High-risk group	3	$>$ 3	$>$ 2,110

CONUT, controlling nutritional status score; EBV DNA, Epstein-Barr virus deoxyribonucleic acid.

AUC = 0.591, 95% CI: 0.532–0.650; DMFS: AUC = 0.610, 95% CI: 0.541–0.678; **Figure 3A–3C**).

There were significant differences among these 3 groups in terms of the 5-year OS (92.6%, 84.1%, and 65.2%;  $P < 0.001$ ) (**Figure 3D**), PFS (83.9%, 76.4%, and 54.3%;  $P < 0.001$ ) (**Figure 3E**), and DMFS (89.8%, 81.1%, and 68.9%;  $P < 0.001$ ) (**Figure 3F**). Notably, HRG and MRG had a significantly worse OS (HRG vs. LGR,  $P < 0.001$ ; MRG vs. LGR,  $P = 0.009$ ) (**Figure 3D**), PFS (HRG vs. LGR,  $P < 0.001$ ; MRG vs. LGR,  $P = 0.013$ )


(**Figure 3E**), and DMFS (HRG vs. LGR,  $P < 0.001$ ; MRG vs. LGR,  $P = 0.003$ ) (**Figure 3F**) than the LRG. Kaplan-Meier analysis and the log-rank test also identified a significantly poorer OS (HRG vs. MGR,  $P = 0.014$ ) (**Figure 3D**) and PFS (HRG vs. MGR,  $P = 0.006$ ) (**Figure 3E**) among patients with a high  $\Delta$ CONUT-EBV DNA score than among those with a medium  $\Delta$ CONUT-EBV DNA score.

The results of our multivariate Cox analysis showed that the  $\Delta$ CONUT-EBV DNA score was an independent prognostic

**Table 4** Characteristics of NPC patients in 3 different risk ( $\Delta$ CONUT-EBV DNA score) groups

Characteristics	LRG N = 217 (%)	MRG N = 170 (%)	HRG N = 46 (%)	P			Bonferroni holm corrected P		
				LRG vs. MRG	LRG vs. HRG	MRG vs. HGR	LRG vs. MRG	LRG vs. HRG	MRG vs. HGR
Age (years)				0.033	0.184	1.000	0.099	0.552	1.000
≤46	127 (58.5)	81 (47.6)	22 (47.8)						
>46	90 (41.5)	89 (52.4)	24 (52.2)						
Gender				0.051	0.042	0.234	0.153	0.126	0.702
Female	65 (30.0)	42 (24.7)	7 (15.2)						
Male	152 (70.0)	128 (75.3)	39 (84.8)						
UICC T stage				0.248	0.702	0.162	0.744	1.000	0.486
1	12 (5.5)	4 (2.4)	4 (8.7)						
2	42 (19.4)	28 (16.5)	10 (21.7)						
3	127 (58.5)	101 (59.4)	23 (50.0)						
4	36 (16.8)	37 (21.8)	9 (19.6)						
UICC N stage				0.001	<0.001	0.334	0.003	<0.001	1.000
0	38 (17.5)	13 (7.6)	1 (2.2)						
1	101 (46.5)	65 (38.2)	17 (37.0)						
2	67 (30.9)	75 (44.1)	20 (43.5)						
3	11 (5.1)	17 (10.0)	8 (17.4)						
Clinical stage				0.002	0.119	0.263	0.006	0.357	0.789
II	26 (12.0)	6 (3.5)	4 (8.7)						
III	146 (67.3)	111 (65.3)	26 (56.5)						
IV	45 (20.7)	53 (31.2)	16 (34.8)						
WHO histology				1.000	0.704	0.679	1.000	1.000	1.000
II	7 (3.2)	6 (3.5)	2 (4.3)						
III	210 (96.8)	164 (96.5)	44 (95.7)						
Smoking status				0.440	0.127	0.451	1.000	0.381	1.000
Non-smoker	143 (65.9)	102 (60.0)	23 (50.0)						
Ex-smoker	13 (6.0)	10 (5.9)	4 (8.7)						
Current smoker	61 (28.1)	58 (34.1)	19 (41.3)						
VCA IgA				0.023	0.412	0.554	0.069	1.000	1.000
≤80	70 (32.3)	37 (21.8)	12 (26.1)						
>80	147 (67.7)	133 (78.2)	34 (73.9)						
EA IgA				0.012	0.940	0.131	0.036	1.000	0.393
≤20	145 (66.8)	92 (54.1)	31 (67.4)						
>20	72 (33.2)	78 (45.9)	15 (32.6)						

NPC, nasopharyngeal carcinoma; LRG, low-risk group =  $\Delta$ CONUT-EBV DNA Score 1 (EBV DNA  $\leq$  2,110 copies/mL); MRG, middle-risk group =  $\Delta$ CONUT-EBV DNA Score 2 (both  $\Delta$ CONUT Score  $\leq$  3 and EBV DNA  $>$  2,110 copies/mL); HRG, high-risk group =  $\Delta$ CONUT-EBV DNA Score 3 (both  $\Delta$ CONUT Score  $>$  3 and EBV DNA  $>$  2,110 copies/mL); CONUT, controlling nutritional status score; N stage, node stage; T stage, tumor stage; UICC, Union for International Cancer Control; WHO, World Health Organization; EBV DNA, Epstein-Barr virus deoxyribonucleic acid; VCA, viral capsid antigen; EA, early antigen; IgA, immunoglobulin a.



**Figure 3** Receiver operating characteristic (ROC) curve analysis of the  $\Delta$ CONUT score, the Epstein-Barr virus deoxyribonucleic acid (EBV DNA) level, and the  $\Delta$ CONUT-EBV DNA score of interest for predicting 5-year overall survival (OS) (A), progression-free survival (PFS) (B), and distant metastasis-free survival (DMFS) (C); Survival analysis for 5-year OS (D), PFS (E), and DMFS (F) based on the  $\Delta$ CONUT-EBV DNA score.

factor for OS (HR: 1.652; 95% CI: 1.242–2.198;  $P = 0.001$ ), PFS (HR: 1.772; 95% CI: 1.385–2.267;  $P < 0.001$ ), and DMFS (HR: 1.874, 95% CI: 1.371–2.562;  $P < 0.001$ ) in patients with advanced NPC who were treated with CCRT (Table 5).

## Discussion

Studies have recently shown that the CONUT score is a prognostic predictor for survival prognosis in many cancer types<sup>11–16</sup>. Moreover, the point at which the nutritional score should be measured during anti-cancer treatment remains unclear. In the present study, the prognostic values of the pre-CONUT, post-CONUT, and  $\Delta$ CONUT scores were evaluated and compared in 433 patients with advanced NPC. The  $\Delta$ CONUT score was found to be superior to the pre-CONUT and post-CONUT scores in terms of the predictive ability for prognosis, and it was an independent prognostic factor for OS. Moreover, our study suggested that a combination of the  $\Delta$ CONUT score and the EBV DNA level was a novel tool for the prediction of poor future outcomes in patients with NPC.

Many reports have suggested that the CONUT score is a useful and convenient biomarker for estimating the nutritional status and predicting prognoses among patients with

non-metastatic renal cell carcinoma<sup>12</sup>, esophageal cancer<sup>13,14</sup>, pancreatic ductal adenocarcinoma<sup>15</sup>, and stage 2/3 gastric cancer<sup>15</sup>. The CONUT score, an immunological and nutritional score, is calculated from the total lymphocyte count and total cholesterol and serum albumin levels<sup>17</sup>. Lymphocytes were found to be associated with cellular immunity against malignant cells<sup>28,29</sup>. Cholesterol reportedly reflects the nutritional status and cancer malignancy status<sup>30,31</sup>. Serum albumin level is an indicator of nutritional status<sup>32</sup>; however, it is more widely recognized as a marker of inflammation<sup>33,34</sup>. Previous studies have shown that low lymphocyte counts and low cholesterol and serum albumin levels are associated with poor prognoses in different cancers<sup>35–39</sup>.

This study is the first to assess the influence of changes in the CONUT score during treatment, so the  $\Delta$ CONUT-EBV DNA score has potential applications in the development of nutritional and individualized treatments for the prognoses of patients with advanced NPC. In the present study, the  $\Delta$ CONUT score was found to be superior to the pre-CONUT and post-CONUT scores in predicting survival for patients with NPC.

The mechanisms explaining why a high  $\Delta$ CONUT score is associated with worse OS are not fully known. Side effects



**Table 5** Univariate and multivariate analysis for 5-year OS, PFS, and DMFS combined with the novel prognosis predictor  $\Delta$ CONUT score and EBV DNA

Endpoint	Variable	Univariate analysis		Multivariate analysis	
		HR (95% CI)	<i>P</i>	HR (95% CI)	<i>P</i>
OS	Age	1.681 (1.125–2.512)	0.011	1.564 (1.045–2.340)	0.030
	Gender	2.105 (1.214–3.648)	0.008	1.925 (1.107–3.347)	0.020
	UICC T stage	0.922 (0.578–1.471)	0.734	0.810 (0.472–1.390)	0.999
	UICC N stage	1.821 (1.219–2.720)	0.003	1.574 (1.046–2.368)	0.030
	Clinical stage	3.077 (0.975–9.712)	0.055	2.654 (0.731–9.638)	0.200
	$\Delta$ CONUT score	1.627 (1.045–2.535)	0.031	1.093 (0.475–2.514)	0.591
	EBV DNA	2.116 (1.396–3.207)	<0.001	0.884 (0.242–3.232)	0.634
	$\Delta$ CONUT-EBV DNA score	1.862 (1.415–2.450)	<0.001	1.652 (1.242–2.198)	0.001
PFS	Age	1.390 (0.976–1.979)	0.068	1.277 (0.894–1.826)	0.149
	Gender	1.357 (0.886–2.078)	0.161	1.262 (0.821–1.941)	0.299
	UICC T stage	0.933 (0.615–1.414)	0.743	0.799 (0.484–1.319)	0.635
	UICC N stage	1.499 (1.053–2.133)	0.025	1.178 (0.787–1.764)	0.130
	Clinical stage	1.955 (0.861–4.441)	0.109	1.903 (0.715–5.067)	0.196
	$\Delta$ CONUT score	1.417 (0.944–2.128)	0.093	0.736 (0.329–1.646)	0.922
	EBV DNA	1.931 (1.341–2.781)	<0.001	0.541 (0.166–1.766)	0.622
	$\Delta$ CONUT-EBV DNA score	1.772 (1.385–2.267)	<0.001	1.772 (1.385–2.267)	<0.001
DMFS	Age	1.031 (0.655–1.624)	0.894	0.928 (0.587–1.466)	0.847
	Gender	1.639 (0.917–2.930)	0.095	1.524 (0.849–2.737)	0.173
	UICC T stage	1.076 (0.619–1.869)	0.796	1.056 (0.555–2.007)	0.836
	UICC N stage	1.819 (1.149–2.881)	0.011	1.497 (0.897–2.497)	0.054
	Clinical stage	2.321 (0.731–7.366)	0.153	1.613 (0.419–6.218)	0.229
	$\Delta$ CONUT score	1.314 (0.774–2.233)	0.312	0.805 (0.275–2.357)	0.479
	EBV DNA	2.376 (1.462–3.860)	<0.001	0.973 (0.204–4.645)	0.523
	$\Delta$ CONUT-EBV DNA score	1.874 (1.371–2.562)	<0.001	1.874 (1.371–2.562)	<0.001

OS, overall survival; HR, hazard ratio; CI, confidence interval; N stage, node stage; T stage, tumor stage; UICC, Union for International Cancer Control; CONUT score, controlling nutritional status score; EBV DNA, Epstein-Barr virus deoxyribonucleic acid; PFS, progression-free survival; DMFS, distant metastasis-free survival.

of anti-cancer treatment affect the nutritional status among patients with head and neck cancers. Oral mucositis is one of the most common side effects of anti-cancer treatments such as radiation therapy, chemotherapy, and immunotherapy<sup>40,41</sup>. It occurs in almost all patients receiving radiation therapy for head and neck cancers<sup>42-44</sup>. Clinically, its symptoms include anorexia, malnutrition (significant weight loss), and systemic infections. It also can influence treatment efficacy by causing

interruptions in treatment or by resulting in dose reductions in chemotherapy and radiotherapy<sup>45</sup>. In turn, dose modification and treatment interruption have been associated with decreased survival<sup>46-48</sup>. Taken together, the  $\Delta$ CONUT score might predict the prognoses of patients with NPC based on a combination of host malnutrition and immunity.

As mentioned in the Introduction, nutritional scores only reflect 1 aspect of the nutritional status and ignore

tumor-related factors. In combination with nasopharyngeal and neck magnetic resonance imaging, nasopharyngoscopy, plasma EBV DNA levels and other blood indicators are routinely assessed in most hospitals. Across numerous studies, plasma EBV DNA levels have been shown to be associated with NPC stage<sup>49-51</sup>, suggesting a reliable and direct correlation between tumor burden and plasma EBV DNA levels<sup>52</sup>. The EBV DNA level is likely a reliable prognostic predictor and tumor-related factor for NPC<sup>3,53,54</sup>. The association between survival outcomes and the plasma EBV DNA levels have been investigated in many studies<sup>20,24,25</sup>. The cut-off values of plasma EBV DNA levels varied across these studies, and an optimal cut-off value of this liquid biopsy marker is still being determined<sup>27,55</sup>. Measurement of plasma EBV DNA levels is commonly used to diagnose NPC and to evaluate anti-cancer treatment and prognosis. Studies support a positive relationship between the EBV DNA level and tumor burden<sup>24,25</sup>. Finally, we further determined the complementary role of the  $\Delta$ CONUT score in combination with pretreatment plasma EBV DNA.

In the subgroup analysis, the  $\Delta$ CONUT score was found to be correlated with the OS of patients with a higher EBV DNA level, but not with the OS of patients with a lower EBV DNA level. Thus, the  $\Delta$ CONUT-EBV DNA score, a novel combination prognostic marker, was introduced to improve the predictive value of the  $\Delta$ CONUT score among patients with advanced NPC. Compared to the  $\Delta$ CONUT score or pretreatment plasma EBV DNA level alone, the  $\Delta$ CONUT-EBV DNA score was more predictive of the OS, PFS, and DMFS for patients with advanced NPC. Thus, patients with NPC who have a medium or high CONUT-EBV DNA score could benefit from a more intensive follow-up, even after curative CCRT with a nutritional intervention during treatment; this may be clinically beneficial in improving the treatment outcomes of these patients.

Nutritional and inflammation status have significant effects on the prognoses of cancer patients. Many studies have already shown that inflammatory markers, nutritional indices, or inflammation-based prognostic scores including red blood cell<sup>56</sup>, total lymphocyte count<sup>57</sup>, albumin<sup>58-60</sup>, hemoglobin<sup>61,62</sup>, serum pre-albumin<sup>63,64</sup>, transferrin<sup>65</sup>, serum C-reactive protein<sup>66</sup>, BMI<sup>7,67-69</sup> and prognostic nutritional index (PNI)<sup>70</sup> are closely associated with treatment outcomes in patients with NPC. Using these blood indicators could only reflect 1 aspect of the nutritional status, so the sensitivity of the scores may differ. These indicators could be easily affected

by metabolism, food, and disease status<sup>71-74</sup>. The utility of BMI and PNI are useful to assess the nutritional status in clinical practice. Individual nutritional factors, such as hemoglobin, albumin, and BMI were not prognostic factors in Wang's cohort of patients with NPC<sup>75</sup>. However, BMI and PNI are easily influenced by gender, age, and disease status. Using only BMI, PNI or 1 blood indicator to assess the nutritional status of patients may therefore introduce errors<sup>76</sup>. These nutritional or immune-nutritional scores are not always reliable in predicting the outcomes of cancers because they lack tumor-related factors. In addition, none of these scores are designed specifically for NPC patients.

However, the tumor-related factors, such as TNM stage and plasma EBV DNA levels only reflect 1 aspect of the tumor-related status. These factors are always reliable in predicting the treatment outcomes of cancers. The EBV DNA level is likely a useful prognostic predictor and tumor-related factor for NPC. The association between survival outcomes and plasma EBV DNA levels have been investigated in many studies<sup>20,24,25</sup>. The cut-off values of the plasma EBV DNA level varied across these studies, and an optimal cut-off value of this liquid biopsy marker is still being determined<sup>27,55</sup>.

The relationship between survival outcomes and nutritional or tumor-related factors needs to be further established in NPC patients, although both nutritional scores and plasma EBV DNA levels are used in the clinic. However, there are only a few clinical studies that have characterized the applicability of different nutritional scores when combined with tumor-related factors and the plasma EBV DNA levels in patients with NPC. The  $\Delta$ CONUT-EBV DNA score includes plasma EBV DNA level and also assesses the change of immune-nutritional status during anti-cancer treatment, resulting in a particularly relevant multidimensional score. The novel combined  $\Delta$ CONUT-EBV DNA scoring system provides more comprehensive prognostic information than individual nutritional indexes.

Our study had some limitations. First, it was a retrospective study performed at a single center. Second, other nutritional scores, such as PNI, BMI, and platelet:lymphocyte ratio, were not assessed. Thus, we do not know if changes in other nutritional scores during the treatment influenced the survival of patients with advanced NPC. Third, information on the side effects of anti-cancer treatment and food intake during the treatment was insufficient for the further analysis of OS, PFS, and DMFS. Thus, further prospective studies are required to establish the value of the  $\Delta$ CONUT-EBV DNA

score as a biomarker of prognosis and treatment outcomes in NPC.

## Conclusions

Taken together, the  $\Delta$ CONUT-EBV DNA score, which is based on the  $\Delta$ CONUT score and pretreatment plasma EBV DNA, has been integrated with the nutritional score and tumor-related factors, which may have more predictive information when compared to only 1 parameter. This score could be important and useful in clinical practice as a convenient, inexpensive biomarker for predicting outcomes for patients with advanced NPC treated with CCRT. As a novel and convenient biomarker, the  $\Delta$ CONUT-EBV DNA score can be used in the development of nutritional and individualized treatments.

## Grant support

This work was supported by grants from the National Key R&D Program of China (Grant Nos. 2017YFC1309003 and 2017YFC0908500), the National Natural Science Foundation of China (Grant Nos. 81425018, 81672868, and 81802775), the Sci-Tech Project Foundation of Guangzhou City (Grant No. 201707020039), the Sun Yat-sen University Clinical Research 5010 Program, the Special Support Plan of Guangdong Province (Grant No. 2014TX01R145), the Natural Science Foundation of Guangdong Province (Grant Nos. 2017A030312003 and 2018A0303131004), the Natural Science Foundation of Guangdong Province for Distinguished Young Scholar (Grant No. 2018B030306001), the Sci-Tech Project Foundation of Guangdong Province (Grant No. 2014A020212103), the Health & Medical Collaborative Innovation Project of Guangzhou City (Grant Nos. 201400000001 and 201803040003), the Pearl River S&T Nova Program of Guangzhou (Grant No. 201806010135), the Planned Science and Technology Project of Guangdong Province (Grant No. 2019B020230002), the National Science & Technology Pillar Program during the Twelfth Five-year Plan Period (Grant No. 2014BAI09B10), the Natural Science Foundation of Guangdong Province (Grant No. 2017A030312003, and Fundamental Research Funds for the Central Universities.

## Conflict of interest statement

No potential conflicts of interest are disclosed.

## References

1. Tan GW, Sivanesan VM, Abdul Rahman FI, Hassan F, Hasbullah HH, Ng CC, et al. A novel and non-invasive approach utilising nasal washings for the detection of nasopharyngeal carcinoma. *Int J Cancer*. 2019; 145: 2260-6.
2. Chan KCA, Woo JKS, King A, Zee BCY, Lam WKJ, Chan SL, et al. Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer. *N Engl J Med*. 2017; 377: 513-22.
3. Lo YM, Chan AT, Chan LY, Leung SF, Lam CW, Huang DP, et al. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. *Cancer Res*. 2000; 60: 6878-81.
4. Lo YM, Chan LY, Chan AT, Leung SF, Lo KW, Zhang J, et al. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. *Cancer Res*. 1999; 59: 5452-5.
5. Leung SF, Lo YM, Chan AT, To KE, To E, Chan LY, et al. Disparity of sensitivities in detection of radiation-naive and postirradiation recurrent nasopharyngeal carcinoma of the undifferentiated type by quantitative analysis of circulating Epstein-Barr virus DNA1,2. *Clin Cancer Res*. 2003; 9: 3431-4.
6. Chen L, Zhang Y, Lai SZ, Li WF, Hu WH, Sun R, et al. 10-Year results of therapeutic ratio by intensity-modulated radiotherapy versus two-dimensional radiotherapy in patients with nasopharyngeal carcinoma. *Oncologist*. 2019; 24: e38-45.
7. Huang JB, Sun RJ, Jiang WJ, Wu P, Zhang L, Xu MQ, et al. Systematic nutrition management for locally advanced nasopharyngeal carcinoma patients undergoing radiotherapy. *Oncotargets Ther*. 2019; 12: 8379-86.
8. Gundog M, Basaran H. Pretreatment low prognostic nutritional index and low albumin-globulin ratio are predictive for overall survival in nasopharyngeal cancer. *Eur Arch Otorhinolaryngol*. 2019; 276: 3221-30.
9. Wei GB, Lu YY, Liao RW, Chen QS, Zhang KQ. Prognostic nutritional index predicts prognosis in patients with metastatic nasopharyngeal carcinoma. *Oncotargets Ther*. 2016; 9: 5955-61.
10. Zeng X, Liu G, Pan Y, Li Y. Prognostic value of clinical biochemistry-based indexes in nasopharyngeal carcinoma. *Front Oncol*. 2020; 10: 146.
11. Harimoto N, Yoshizumi T, Inokuchi S, Itoh S, Adachi E, Ikeda Y, et al. Prognostic significance of preoperative controlling nutritional status (CONUT) score in patients undergoing hepatic resection for hepatocellular carcinoma: a multi-institutional study. *Ann Surg Oncol*. 2018; 25: 3316-23.
12. Song H, Xu B, Luo C, Zhang Z, Ma B, Jin J, et al. The prognostic value of preoperative controlling nutritional status score in non-metastatic renal cell carcinoma treated with surgery: a retrospective single-institution study. *Cancer Manag Res*. 2019; 11: 7567-75.
13. Hikage M, Taniyama Y, Sakurai T, Sato C, Takaya K, Okamoto H, et al. The influence of the perioperative nutritional status on the survival outcomes for esophageal cancer patients with neoadjuvant chemotherapy. *Ann Surg Oncol*. 2019; 26: 4744-53.

14. Toyokawa T, Kubo N, Tamura T, Sakurai K, Amano R, Tanaka H, et al. The pretreatment Controlling Nutritional Status (CONUT) score is an independent prognostic factor in patients with resectable thoracic esophageal squamous cell carcinoma: results from a retrospective study. *BMC Cancer*. 2016; 16: 722.
15. Terasaki F, Sugiura T, Okamura Y, Ito T, Yamamoto Y, Ashida R, et al. The preoperative controlling nutritional status (CONUT) score is an independent prognostic marker for pancreatic ductal adenocarcinoma. *Updates Surg*. 2020; 73: 251–9.
16. Ryo S, Kanda M, Ito S, Mochizuki Y, Teramoto H, Ishigure K, et al. The controlling nutritional status score serves as a predictor of short- and long-term outcomes for patients with stage 2 or 3 gastric cancer: analysis of a multi-institutional data set. *Ann Surg Oncol*. 2019; 26: 456–64.
17. Ignacio de Ulibarri J, Gonzalez-Madrono A, de Villar NG, Gonzalez P, Gonzalez B, Mancha A, et al. CONUT: a tool for controlling nutritional status. First validation in a hospital population. *Nutr Hosp*. 2005; 20: 38–45.
18. Chan AT. Nasopharyngeal carcinoma. *Ann Oncol*. 2010; 21 Suppl 7: vii308–12.
19. Lee AW, Ma BB, Ng WT, Chan AT. Management of nasopharyngeal carcinoma: current practice and future perspective. *J Clin Oncol*. 2015; 33: 3356–64.
20. Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. *N Engl J Med*. 2004; 350: 2461–70.
21. Guo R, Tang LL, Mao YP, Du XJ, Chen L, Zhang ZC, et al. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma. *Cancer*. 2019; 125: 79–89.
22. Lee VH, Kwong DL, Leung TW, Choi CW, O'Sullivan B, Lam KO, et al. The addition of pretreatment plasma Epstein-Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification. *Int J Cancer*. 2019; 144: 1713–22.
23. Xu C, Chen YP, Liu X, Li WF, Chen L, Mao YP, et al. Establishing and applying nomograms based on the 8th edition of the UICC/AJCC staging system to select patients with nasopharyngeal carcinoma who benefit from induction chemotherapy plus concurrent chemoradiotherapy. *Oral Oncol*. 2017; 69: 99–107.
24. Ma BB, King A, Lo YM, Yau YY, Zee B, Hui EP, et al. Relationship between pretreatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma. *Int J Radiat Oncol Biol Phys*. 2006; 66: 714–20.
25. Chan KC, Chan AT, Leung SF, Pang JC, Wang AY, Tong JH, et al. Investigation into the origin and tumoral mass correlation of plasma Epstein-Barr virus DNA in nasopharyngeal carcinoma. *Clin Chem*. 2005; 51: 2192–5.
26. McMillan GH. Looking at problems—a new approach to injury records. *Occup Health (Lond)*. 1980; 32: 286–98.
27. Qu H, Huang Y, Zhao S, Zhou Y, Lv W. Prognostic value of Epstein-Barr virus DNA level for nasopharyngeal carcinoma: a meta-analysis of 8128 cases. *Eur Arch Otorhinolaryngol*. 2020; 277: 9–18.
28. Romaniuk A, Lyndin M. Immune microenvironment as a factor of breast cancer progression. *Diagn Pathol*. 2015; 10: 79.
29. Bates JP, Derakhshandeh R, Jones L, Webb TJ. Mechanisms of immune evasion in breast cancer. *BMC Cancer*. 2018; 18: 556.
30. Chen P, Han L, Wang C, Jia Y, Song Q, Wang J, et al. Preoperative serum lipids as prognostic predictors in esophageal squamous cell carcinoma patients with esophagectomy. *Oncotarget*. 2017; 8: 41605–19.
31. Lee H, Jeong CW, Kwak C, Kim HH, Seo SI, Lee HM, et al. Preoperative cholesterol level is associated with worse pathological outcomes and postoperative survival in localized renal cell carcinoma patients: a propensity score-matched study. *Clin Genitourin Cancer*. 2017; 15: e935–41.
32. de Ulibarri Perez JI, Fernandez G, Rodriguez Salvanes F, Diaz Lopez AM. Nutritional screening; control of clinical undernutrition with analytical parameters. *Nutr Hosp*. 2014; 29: 797–811.
33. Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. *Future Oncol*. 2010; 6: 149–63.
34. McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. *Curr Opin Clin Nutr Metab Care*. 2009; 12: 223–6.
35. Remark R, Becker C, Gomez JE, Damotte D, Dieu-Nosjean MC, Sautes-Fridman C, et al. The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome. *Am J Respir Crit Care Med*. 2015; 191: 377–90.
36. Campian JL, Sarai G, Ye X, Marur S, Grossman SA. Association between severe treatment-related lymphopenia and progression-free survival in patients with newly diagnosed squamous cell head and neck cancer. *Head Neck*. 2014; 36: 1747–53.
37. Deng W, Xu C, Liu A, van Rossum PSN, Deng W, Liao Z, et al. The relationship of lymphocyte recovery and prognosis of esophageal cancer patients with severe radiation-induced lymphopenia after chemoradiation therapy. *Radiother Oncol*. 2019; 133: 9–15.
38. Kanda M, Tanaka C, Kobayashi D, Uda H, Inaoka K, Tanaka Y, et al. Preoperative albumin-bilirubin grade predicts recurrences after radical gastrectomy in patients with pT2–4 gastric cancer. *World J Surg*. 2018; 42: 773–81.
39. Wu N, Chen G, Hu H, Pang L, Chen Z. Low pretherapeutic serum albumin as a risk factor for poor outcome in esophageal squamous cell carcinomas. *Nutr Cancer*. 2015; 67: 481–5.
40. Pico JL, Avila-Garavito A, Naccache P. Mucositis: its occurrence, consequences, and treatment in the oncology setting. *Oncologist*. 1998; 3: 446–51.
41. Bensinger W, Schubert M, Ang KK, Brizel D, Brown E, Eilers JG, et al. NCCN Task Force Report. prevention and management of mucositis in cancer care. *J Natl Compr Canc Netw*. 2008; 6 (Suppl 1): S1–21; quiz S22–24.
42. Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. *Cancer*. 2004; 100: 1995–2025.

43. Mortensen HR, Overgaard J, Specht L, Overgaard M, Johansen J, Evensen JF, et al. Prevalence and peak incidence of acute and late normal tissue morbidity in the DAHANCA 6&7 randomised trial with accelerated radiotherapy for head and neck cancer. *Radiother Oncol.* 2012; 103: 69-75.
44. Blijlevens N, Schwenkgenks M, Bacon P, D'Addio A, Einsele H, Maertens J, et al. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy—European Blood and Marrow Transplantation Mucositis Advisory Group. *J Clin Oncol.* 2008; 26: 1519-25.
45. Trotti A, Bellm LA, Epstein JB, Frame D, Fuchs HJ, Gwede CK, et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. *Radiother Oncol.* 2003; 66: 253-62.
46. Rosenthal DI. Consequences of mucositis-induced treatment breaks and dose reductions on head and neck cancer treatment outcomes. *J Support Oncol.* 2007; 5: 23-31.
47. Russo G, Haddad R, Posner M, Machtay M. Radiation treatment breaks and ulcerative mucositis in head and neck cancer. *Oncologist.* 2008; 13: 886-98.
48. Campos MI, Campos CN, Aarestrup FM, Aarestrup BJ. Oral mucositis in cancer treatment: natural history, prevention and treatment. *Mol Clin Oncol.* 2014; 2: 337-40.
49. Lo Y, Chan L, Lo K, Leung S, Zhang J, Chan A, et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. *Cancer Res.* 1999; 59: 1188-91.
50. Vo J, Nei W, Hu M, Phyo W, Wang F, Fong K, et al. Comparison of circulating tumour cells and circulating cell-free Epstein-Barr virus DNA in patients with nasopharyngeal carcinoma undergoing radiotherapy. *Sci Rep.* 2016; 6: 13.
51. Prayongrat A, Chakkabat C, Kannarunimit D, Hansasuta P, Lertbutsayanukul C. Prevalence and significance of plasma Epstein-Barr Virus DNA level in nasopharyngeal carcinoma. *J Radiat Res.* 2017; 58: 509-16.
52. Tan R, Phua S, Soong Y, Oon L, Chan K, Lucky S, et al. Clinical utility of Epstein-Barr virus DNA and other liquid biopsy markers in nasopharyngeal carcinoma. *Cancer Commun (London, England).* 2020; 40: 564-85.
53. Chan A, Lo Y, Zee B, Chan L, Ma B, Leung S, et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. *J Natl Cancer Inst.* 2002; 94: 1614-9.
54. Wang W, Twu C, Chen H, Jan J, Jiang R, Chao J, et al. Plasma EBV DNA clearance rate as a novel prognostic marker for metastatic/recurrent nasopharyngeal carcinoma. *Clin Cancer Res.* 2010; 16: 1016-24.
55. Zhang J, Shu C, Song Y, Li Q, Huang J, Ma X. Epstein-Barr virus DNA level as a novel prognostic factor in nasopharyngeal carcinoma: a meta-analysis. *Medicine.* 2016; 95: e5130.
56. Yao ZH, Tian GY, Wan YY, Kang YM, Guo HS, Liu QH, et al. Prognostic nutritional index predicts outcomes of malignant pleural mesothelioma. *J Cancer Res Clin Oncol.* 2013; 139: 2117-23.
57. Chen K, Liu Y, Li W, Chen J, Gu Y, Geng Q, et al. The prognostic nutritional index predicts survival for patients with extranodal natural killer/T cell lymphoma, nasal type. *Ann Hematol.* 2015; 94: 1389-400.
58. Li G, Gao J, Liu Z, Tao Y, Xu B, Tu Z, et al. Influence of pretreatment ideal body weight percentile and albumin on prognosis of nasopharyngeal carcinoma: long-term outcomes of 512 patients from a single institution. *Head Neck.* 2014; 36: 660-6.
59. Liu S, Tsai W, Wong Y, Lin J, Poon C, Chao S, et al. Nutritional factors and survival of patients with oral cancer. *Head Neck.* 2006; 28: 998-1007.
60. Tartari R, Ulbrich-Kulczynski J, Filho A. Measurement of mid-arm muscle circumference and prognosis in stage IV non-small cell lung cancer patients. *Oncol Lett.* 2013; 5: 1063-7.
61. Xie X, Yao M, Chen X, Lu W, Lv Q, Wang K, et al. Reduced red blood cell count predicts poor survival after surgery in patients with primary liver cancer. *Medicine.* 2015; 94: e577.
62. Mayr N, Wang J, Zhang D, Montebello J, Grecula J, Lo S, et al. Synergistic effects of hemoglobin and tumor perfusion on tumor control and survival in cervical cancer. *Int J Radiat Oncol Biol Phys.* 2009; 74: 1513-21.
63. Iwasa M. [Nutritional assessment of patients with esophageal cancer. "Nutritional Assessment Index (NAI)" to estimate nutritional conditions in pre- and postoperative period]. *Nihon Geka Gakkai Zasshi.* 1983; 84: 1031-41.
64. Onizuka K, Migita S, Yamada H, Matsumoto I. [Serum protein fractions in patients with laryngeal cancer undergoing radiation therapy. Possibility as a prognostic factor]. *Fukuoka Igaku Zasshi.* 1999; 90: 46-58.
65. Lai S, Perng R. Impact of nutritional status on the survival of lung cancer patients. *Zhonghua Yi Xue Za Zhi.* 1998; 61: 134-40.
66. Tang L, Li C, Chen Q, Zhang L, Lai X, He Y, et al. High-sensitivity C-reactive protein complements plasma Epstein-Barr virus deoxyribonucleic acid prognostication in nasopharyngeal carcinoma: a large-scale retrospective and prospective cohort study. *Int J Radiat Oncol Biol Phys.* 2015; 91: 325-36.
67. OuYang PY, Zhang LN, Tang J, Lan XW, Xiao Y, Gao YH, et al. Evaluation of body mass index and survival of nasopharyngeal carcinoma by propensity-matched analysis: an observational case-control study. *Medicine (Baltimore).* 2016; 95: e2380.
68. Sinicrope F, Foster N, Yothers G, Benson A, Seitz J, Labianca R, et al. Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. *Cancer.* 2013; 119: 1528-36.
69. Zhang S, Yang H, Luo K, Huang Q, Chen J, Yang F, et al. The impact of body mass index on complication and survival in resected oesophageal cancer: a clinical-based cohort and meta-analysis. *Br J Cancer.* 2013; 109: 2894-903.
70. Yang L, Xia L, Wang Y, Hong S, Chen H, Liang S, et al. Low prognostic nutritional index (PNI) predicts unfavorable distant metastasis-free survival in nasopharyngeal carcinoma: a propensity score-matched analysis. *PLoS One.* 2016; 11: e0158853.

71. Fuhrman M, Charney P, Mueller C. Hepatic proteins and nutrition assessment. *J Am Diet Assoc.* 2004; 104: 1258-64.
72. Dequanter D, Lothaire P. Serum albumin concentration and surgical site identify surgical risk for major post-operative complications in advanced head and neck patients. *B-ENT.* 2011; 7: 181-3.
73. Guerra L, Rosa A, Romani R, Gurski R, Schirmer C, Krueel C. Serum transferrin and serum prealbumin as markers of response to nutritional support in patients with esophageal cancer. *Nutr Hosp.* 2009; 24: 241-2.
74. Hong J, Hua Y, Su L, Zhang H, Lv W, Chen X, et al. Modified-nutrition index is a significant prognostic factor for the overall survival of the nasopharyngeal carcinoma patients who undergo intensity-modulated radiotherapy. *Nutr Cancer.* 2017; 69: 1011-8.
75. Wang Y, He S, Cai X, Chen H, Yang X, Lu L, et al. The novel prognostic score combining red blood cell distribution width and body mass index (COR-BMI) has prognostic impact for survival outcomes in nasopharyngeal carcinoma. *J Cancer.* 2018; 9: 2295-301.
76. Lin Y, Chang K, Lin Y, Chang T. Evaluation of effect of body mass index and weight loss on survival of patients with nasopharyngeal carcinoma treated with intensity-modulated radiation therapy. *Radiat Oncol.* 2015; 10: 136.

**Cite this article as:** Lu H, Guo S, Liu L, Chen Q, Liang Y, Liu S, et al. Prognostic significance of a combined and controlled nutritional status score and EBV-DNA in patients with advanced nasopharyngeal carcinoma: a long-term follow-up study. *Cancer Biol Med.* 2022; 19: 551-564. doi: 10.20892/j.issn.2095-3941.2020.0627